Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2017 May 22;99(1):70–79. doi: 10.1016/j.ijrobp.2017.05.022

Figure 3.

Figure 3

A cardiac dose threshold of heart volume (HV)35 >10% predicts PCE development in both patient groups. (A) In the patients from the prospective trial, the cumulative incidence of PCE was significantly higher for patients with HV35 >10% (38.2% vs. 21.1% for HV35 ≤10% at 1 year, and 56.2% vs. 27.1% HV35 ≤10% at 2 years; log-rank p=0.003). (B) Results were similar findings in the retrospective (validation) patient group: the cumulative incidence of PCE was higher for those with HV35 >10% than for those with HV35 ≤10% (37.7% vs. 23.3% at 1 year, and 49.5% vs. 34.5% at 2 years; log-rank p=0.006).